| Literature DB >> 28348590 |
Ahmed A Abdulhaq1, Vinod Kumar Basode2, Anwar M Hashem3, Ahmed S Alshrari4, Nassrin A Badroon5, Ahmed M Hassan5, Tagreed L Alsubhi5, Yahia Solan6, Saleh Ejeeli2, Esam I Azhar7.
Abstract
We undertook enhanced surveillance of those presenting with respiratory symptoms at five healthcare centers by testing all symptomatic outpatients between November 2013 and January 2014 (winter time). Nasal swabs were collected from 182 patients and screened for MERS-CoV as well as other respiratory viruses using RT-PCR and multiplex microarray. A total of 75 (41.2%) of these patients had positive viral infection. MERS-CoV was not detected in any of the samples. Human rhinovirus (hRV) was the most detected pathogen (40.9%) followed by non-MERS-CoV human coronaviruses (19.3%), influenza (Flu) viruses (15.9%), and human respiratory syncytial virus (hRSV) (13.6%). Viruses differed markedly depending on age in which hRV, Flu A, and hCoV-OC43 were more prevalent in adults and RSV, hCoV-HKU1, and hCoV-NL63 were mostly restricted to children under the age of 15. Moreover, coinfection was not uncommon in this study, in which 17.3% of the infected patients had dual infections due to several combinations of viruses. Dual infections decreased with age and completely disappeared in people older than 45 years. Our study confirms that MERS-CoV is not common in the southwestern region of Saudi Arabia and shows high diversity and prevalence of other common respiratory viruses. This study also highlights the importance and contribution of enhanced surveillance systems for better infection control.Entities:
Year: 2017 PMID: 28348590 PMCID: PMC5350310 DOI: 10.1155/2017/4247853
Source DB: PubMed Journal: Adv Virol ISSN: 1687-8639
Summary of demography characteristics of patients with upper respiratory tract infection in the community in Jazan province, Saudi Arabia.
| Variable | Infected | All subjects |
|---|---|---|
| Number (%) | Number (%) | |
| Total number | 75 (41.2) | 182 (100) |
| Gender | ||
| Male | 54 (72.0) | 131 (72.0) |
| Female | 21 (28.0) | 51 (28.0) |
| Nationality | ||
| Saudi | 63 (84.0) | 155 (85.2) |
| Non-Saudi | 12 (16.0) | 27 (14.8) |
| Smoking | ||
| Yes | 13 (17.3) | 33 (18.1) |
| No | 62 (82.7) | 149 (81.9) |
| Age group (years) | ||
| <15 | 26 (34.7) | 62 (34.1) |
| 15–24 | 16 (21.3) | 48 (26.4) |
| 25–34 | 15 (20.0) | 40 (22.0) |
| 35–44 | 13 (17.3) | 21 (11.5) |
| >45 | 5 (6.7) | 11 (6.0) |
| Healthcare center¶ | ||
| Center 1 | 2 (2.7) | 2 (1.1) |
| Center 2 | 10 (13.3) | 19 (10.4) |
| Center 3 | 36 (48.0) | 68 (37.4) |
| Center 4 | 22 (29.3) | 87 (47.8) |
| Center 5 | 5 (6.7) | 6 (3.3) |
¶Center 1 (Al Rowdah District, North), Center 2 (Al Rowdah District, South), Center 3 (Area 5), Center 4 (Al Safa District), and Center 5 (Al Shatea District).
Viruses identified in patients with upper respiratory tract infection.
| Viruses | Single infections ( | Coinfections ( | All infections ( |
|---|---|---|---|
| Number (%) | Number (%) | Number (%) | |
| hRV | 29 (46.8) | 7 (26.9) | 36 (40.9) |
| hCoV-OC43 | 9 (14.5) | 5 (19.2) | 14 (15.9) |
| hCoV-HKU1 | 2 (3.2) | 0 | 2 (2.3) |
| hCoV-NL63 | 1 (1.6) | 0 | 1 (1.1) |
| hRSV-A | 1 (1.6) | 2 (7.7) | 3 (3.4) |
| hRSV-B | 7 (11.3) | 2 (7.7) | 9 (10.2) |
| FluA | 7 (11.3) | 5 (19.2) | 12 (13.6) |
| FluB | 2 (3.2) | 0 (0.0) | 2 (2.3) |
| EV | 2 (3.2) | 1 (3.9) | 3 (3.4) |
| hAdv | 1 (1.6) | 4 (15.4) | 5 (5.7) |
| hMPVA | 1 (1.6) | 0 | 1 (1.1) |
¶Coinfections include all viruses detected from the 13 coinfected patients (2 × 13).
$Includes viruses detected in single infections (62) and in coinfections (26).
Demographic data of patients with upper respiratory tract infection by pathogen.
| Infecting viruses | Number of patients | Age (years) | Gender | |||||
|---|---|---|---|---|---|---|---|---|
| Number (%) | Number (%) | |||||||
| <15 | 15–24 | 25–34 | 35–44 | >45 | Male | Female | ||
| Total number | 75 | 26 (34.7) | 16 (21.3) | 15 (20.0) | 13 (17.3) | 5 (6.7) | 54 (72.0) | 21 (28.0) |
| hRV | 29 | 5 (19.2) | 6 (37.5) | 9 (60.0) | 5 (38.5) | 4 (80.0) | 24 (82.8) | 5 (17.2) |
| hCoV-OC43 | 9 | 3 (11.5) | 1 (6.3) | 1 (6.66) | 4 (30.8) | 0 | 7 (77.8) | 2 (22.2) |
| hCoV-HKU1 | 2 | 1 (3.8) | 0 | 0 | 0 | 1 (20.0) | 0 | 2 (100) |
| hCoV-NL63 | 1 | 1 (3.8) | 0 | 0 | 0 | 0 | 1 (100) | 0 |
| hRSV-A | 1 | 0 | 1 (6.3) | 0 | 0 | 0 | 1 (100) | 0 |
| hRSV-B | 7 | 5 (19.2) | 2 (12.5) | 0 | 0 | 0 | 4 (57.1) | 3 (42.9) |
| FluA | 7 | 2 (7.7) | 1 (6.3) | 2 (13.33) | 2 (15.4) | 0 | 5 (71.4) | 2 (28.6) |
| FluB | 2 | 1 (3.8) | 0 | 1 (6.66) | 0 | 0 | 1 (50) | 1 (50) |
| EV | 2 | 2 (7.7) | 0 | 0 | 0 | 0 | 1 (50) | 1 (50) |
| hAdv | 1 | 0 | 1 (6.3) | 0 | 0 | 0 | 1 (100) | 0 |
| hMPVA | 1 | 0 | 0 | 1 (6.66) | 0 | 0 | 1 (100) | 0 |
| hRV + FluA | 1 | 0 | 1 (6.3) | 0 | 0 | 0 | 1 (100) | 0 |
| hAdv + hRV | 4 | 2 (7.7) | 1 (6.3) | 1 (6.66) | 0 | 0 | 2 (50) | 2 (50) |
| hCoV-OC43 + FluA | 3 | 1 (3.8) | 1 (6.3) | 0 | 1 (7.7) | 0 | 3 (100) | 0 |
| hRV + hRSV-A | 1 | 1 (3.8) | 0 | 0 | 0 | 0 | 1 (100) | 0 |
| hRSV-A + hRSV-B | 1 | 1 (3.8) | 0 | 0 | 0 | 0 | 0 | 1 (100) |
| hCoV-OC43 + hRSV-B | 1 | 0 | 1 (6.3) | 0 | 0 | 0 | 1 (100) | 0 |
| FluA + EV | 1 | 1 (3.8) | 0 | 0 | 0 | 0 | 0 | 1 |
| hCoV-OC43 + hRV | 1 | 0 | 0 | 0 | 1 (7.7) | 0 | 0 | 1 |
Clinical symptoms in infected and noninfected patients.
| Clinical | Infected ( | Non-infected ( |
|---|---|---|
| Number (%) | Number (%) | |
| Fever | 54 (72) | 65 (60.7) |
| Cough | 68 (90.7) | 96 (89.7) |
| Runny nose | 67 (89.3) | 80 (74.8) |
| Wheezing | 17 (22.7) | 9 (8.4) |
| Headache | 36 (48.0) | 38 (35.5) |
| Sore throat | 62 (82.7) | 88 (82.2) |
| Difficult breathing | 8 (10.7) | 11 (10.3) |
| Lethargy | 30 (40.0) | 27 (25.2) |
| Nausea | 10 (13.3) | 10 (9.3) |
| Nasal congestion | 59 (78.6) | 72 (67.3) |
| Earache | 7 (9.3) | 12 (11.2) |
Significant p value < 0.05.
Clinical symptoms in patients with single infections and coinfections.
| Clinical symptoms | Single infection ( | Coinfection ( |
|---|---|---|
| Number (%) | Number (%) | |
| Fever | 43 (69.4) | 11 (84.6) |
| Cough | 55 (88.7) | 13 (100) |
| Runny nose | 56 (90.3) | 11 (84.6) |
| Wheezing | 13 (21) | 4 (30.8) |
| Headache | 29 (46.8) | 7 (53.8) |
| Sore throat | 51 (82.3) | 11 (84.6) |
| Difficult breathing | 5 (8.1) | 3 (23.1) |
| Lethargy | 25 (40.3) | 5 (38.5) |
| Nausea | 8 (12.9) | 2 (15.4) |
| Nasal congestion | 52 (83.9) | 7 (53.8) |
| Earache | 4 (6.5) | 3 (23.1) |
Significant p value < 0.05.
Figure 1Map of Saudi Arabia showing the administrative provinces. Jazan province (red) is in the southwestern region of the country and north of Yemen.